Prognostic values of pathologic findings and hypoxia markers in 21 patients with salivary duct carcinoma

Journal of Surgical Oncology

Volumn 97, Issue 7, 2008, Pages 596-600

  Roh, Jong Lyel ^a   Cho, Kyung Ja ^a   Gui, Young Kwon ^a   Choi, Seung Ho ^a   Soon, Yuhl Nam ^a   Sang, Yoon Kim ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Biomarkers; Hypoxia; Prognostic predictor; Salivary duct carcinoma; Survival

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; ERYTHROPOIETIN RECEPTOR; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; NECK DISSECTION; PRIORITY JOURNAL; PROGNOSIS; SALIVARY GLAND CARCINOMA; SALIVARY GLAND DUCT; SALIVARY GLAND DUCT CARCINOMA; STATISTICAL ANALYSIS; SURVIVAL RATE; TISSUE MICROARRAY;

ADULT; AGED; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARBONIC ANHYDRASES; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, ERYTHROPOIETIN; SALIVARY GLAND NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 44849083293     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21045     Document Type: Article

References (25)

1. Kleinsasser O, Klein HJ, Hubner G: Salivary duct carcinoma: A group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 1968; 192:100-105.
2. Spitz MR, Batsakis JG: Major salivary gland carcinoma. Descriptive epidemiology and survival of 498 patients. Arch Otolaryngol 1984;110:45-49.
3. Brandwein MS, Jagirdar J, Patil J, et al.: Salivary duct carcinoma (cribriform salivary carcinoma of excretory ducts). A clinicopathologic and immunohistochemical study of 12 cases. Cancer 1990;65:2307-2314.
4. Lewis JE, McKinney BC, Weiland LH, et al.: Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996;77:223-230.
5. Jaehne M, Roeser K, Jaekel T, et al.: Clinical and immunohistologic typing of salivary duct carcinoma: A report of 50 cases. Cancer 2005;103:2526-2533.
6. Felix A, El-Naggar AK, Press MF, et al.: Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 1996; 27:561-566.
7. Barnes L, Rao U, Contis L, et al.: Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol 1994;78:74-80.
8. Fan CY, Wang J, Barnes EL: Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: An immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol 2000;24:579-586.
9. Etges A, Pinto DS, Jr., Kowalski LP, et al.: Salivary duct carcinoma: Immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol 2003;56:914-918.
10. Cornolti G, Ungari M, Morassi ML, et al.: Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg 2007;133:1031-1036.
11. Nabili V, Tan JW, Bhuta S, et al.: Salivary duct carcinoma: A clinical and histologic review with implications for trastuzumab therapy. Head Neck 2007;29:907-912.
12. Brizel DM, Sibley GS, Prosnitz LR, et al.: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-289.
13. Kaanders JH, Wijffels KI, Marres HA, et al.: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-7074.
14. Jonathan RA, Wijffels KI, Peeters W, et al.: The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 2006;79:288-297.
15. Hoogsteen IJ, Marres HA, Bussink J, et al.: Tumor microenvironment in head and neck squamous cell carcinomas: Predictive value and clinical relevance of hypoxic markers: A review. Head Neck 2007;29:591-604.
16. Janssen HL, Haustermans KM, Balm AJ, et al.: Hypoxia in head and neck cancer: How much, how important? Head Neck 2005; 27:622-638.
17. Green FL, Page DL, Fleming ID, et al.: AJCC Cancer Staging Manual. 6th edition. New York: Springer-Verlag; 2002; pp. 23-32.
18. Delgado R, Vuitch F, Albores-Saavedra J: Salivary duct carcinoma. Cancer 1993;72:1503-1512.
19. Guzzo M, Di Palma S, Grandi C, et al.: Salivary duct carcinoma: Clinical characteristics and treatment strategies. Head Neck 1997;19:126-133.
20. Luna MA, Batsakis JG, Ordóñez NG, et al.: Salivary gland adenocarcinomas: A clinicopathologic analysis of three distinctive types. Semin Diagn Pathol 1987;4:117-135.
21. Colmenero Ruiz C, Patron Romero M, Martin Perez M: Salivary duct carcinoma: A report of nine cases. J Oral Maxillofac Surg 1993;51:641-646.
22. Hosal AS, Fan C, Barnes L, Myers EN: Salivary duct carcinoma. Otolaryngol Head Neck Surg 2003;129:720-725.
23. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al.: Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006;24:727-735.
24. Dimery IW, Legha SS, Shirinian M, et al.: Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 1990;8:1056-1062.
25. Dodd RL, Slevin NJ: Salivary gland adenoid cystic carcinoma: A review of chemotherapy and molecular therapies. Oral Oncol 2006;42:759-769.